Researchers Develop ‘Trojan Horse’ Drug That Tricks, Then Kills Cancer Cells
studyfinds.org
studyfinds.org
Unlike the dog dewormer, today’s Paclitaxel regimens are quite toxic. Interestingly, most of the toxicity comes from the method of delivery [1], not the drug itself. It’s actually why the way we give it (infrequent doses) actually promotes recurrence in some cases. This post talks about a much less toxic method of delivery, which explains why they can up the dose of the drug significantly while still being much safer.
With a therapeutic like the one described in the post I'd be really interested to know the cold, honest numbers on recurrence - not to be negative, just to understand where this falls with regards to other treatments.
Obviously it can take years for recurrence rates to shake out and become evident, but I feel like in the last few years we've been hearing a lot about promising therapies (CAR-T, Harvard CD-47 trials, this) that ultimately fall off the common radar.
It could be that these therapies are the real deal and are quietly saving lives now (I know CAR-T has shown real promise in liquid tumors), but it's worrying when news around this research falls silent as it makes it seem like they aren't providing lasting cures.
There are a lot of fly-by-night stories like this for a variety of reasons, be it ongoing research, funding seeking, or otherwise. I do believe the Benzimidazole class of medication mentioned is worth taking a deeper look at however—it seems to be a common thread over many of these.
Sometimes the reason something hasn’t seen use is more than the question of whether it’s clinically viable or not.
As for lasting results, most aren't cures, it's about improving the overall survivability, meaning time until the next treatment option opens up. A lot of these options give you a few months at most which is a big improvement and gives you a chance until the next thing comes out. The reason for this is that we're commonly talking about late stage cancers (3/4). Early stage cancers that haven't spread are cut out before they spread which is the best possible option as it's the highest likelihood of a cure.
There is also no evidence it promotes cancer recurrence.
I say toxic relative to the Benzimidazole family of medication, and though Paclitaxel’s worst side effects, like the neuropathy you mention, come cumulatively with chronic use, it’s more common side effects are still numerous, including a few serious ones, from sources I find.
And “promotes cancer recurrence” was a poor choice of term on my part. What I mean here is the time between doses is wide enough to permit recurrence in some cases.
If your company is a for profit share company making inroads in this, then what is the point of donating money when the real progress seems to happens on the invested money looking for returns
The nasty thing about cancers is that their development is probabilistic. Some cancers may develop in a more common way for which there are already effective drugs. But you might also get unlucky and get a less typical/less studied form of a cancer and then your treatment options are much worse.
It appears a neurosurgery professor at Johns Hopkins that independently discovered the link was interested in it for that very reason [3].
[0]: https://news.ycombinator.com/item?id=20486893
[1]: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1874411/
[2]: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5403762/
[3]: https://www.npr.org/sections/health-shots/2017/01/30/5124002...